BCL2L2 is a probable target for novel 14q11.2 amplification detected in a non-small cell lung cancer cell line

Tsutomu Kawasaki, Sana Yokoi, Hitoshi Tsuda, Hiroyuki Izumi, Ken Ichi Kozaki, Shinsuke Aida, Yuichi Ozeki, Yasuyuki Yoshizawa, Issei Imoto, Johji Inazawa

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Amplification of chromosomal DNA is thought to be one of the mechanisms that activates cancer-related genes in tumors. In a previous genome-wide screening of DNA copy number aberrations in a panel of non-small cell lung cancer (NSCLC) cell lines using an in-house bacterial artificial chromosome-based array, we identified a novel amplification at 14q11.2 in HUT29 cells derived from human lung adenocarcinoma. To identify the most likely target for the 14q11.2 amplification, we determined the extent of the amplicon by fluorescence in.situ hybridization and then analyzed NSCLC cell lines for the expression levels of 28 genes present within the 1-Mb amplified region. Significant overexpression in the HUT29 cell line with amplification, relatively frequent overexpression in additional NSCLC cell lines compared with an immortalized normal lung epithelial cell line, and reported information about the function of each candidate gene prompted us to characterize the BCL2-like2 (BCL2L2) gene, a prosurvival member of the BCL2 family, as the most likely target for the 14q11.2 amplicon. Immunohistochemical analysis of 61 primary cases of lung adenocarcinoma demonstrated that BCL2L2 overexpression was significantly associated with tumor stage and differentiation status, and tended to be associated with a poorer prognosis. Downregulation of BCL2L2 expression using small interfering RNA dramatically inhibited the growth of HUT29 cells, but showed no effect on anticancer reagent-induced cell death of the same cell line. These findings demonstrate that overexpressed BCL2L2, through amplification or other mechanisms, promotes the growth of NSCLC, especially the adenocarcinoma subtype, and might be a therapeutic target.

Original languageEnglish
Pages (from-to)1070-1077
Number of pages8
JournalCancer Science
Volume98
Issue number7
DOIs
Publication statusPublished - Jul 2007
Externally publishedYes

Fingerprint

Non-Small Cell Lung Carcinoma
Cell Line
Genes
Bacterial Artificial Chromosomes
Neoplasm Genes
DNA
Growth
Small Interfering RNA
Neoplasms
Adenocarcinoma
Cell Death
Down-Regulation
Fluorescence
Epithelial Cells
Genome
Lung
Adenocarcinoma of lung

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Kawasaki, T., Yokoi, S., Tsuda, H., Izumi, H., Kozaki, K. I., Aida, S., ... Inazawa, J. (2007). BCL2L2 is a probable target for novel 14q11.2 amplification detected in a non-small cell lung cancer cell line. Cancer Science, 98(7), 1070-1077. https://doi.org/10.1111/j.1349-7006.2007.00491.x

BCL2L2 is a probable target for novel 14q11.2 amplification detected in a non-small cell lung cancer cell line. / Kawasaki, Tsutomu; Yokoi, Sana; Tsuda, Hitoshi; Izumi, Hiroyuki; Kozaki, Ken Ichi; Aida, Shinsuke; Ozeki, Yuichi; Yoshizawa, Yasuyuki; Imoto, Issei; Inazawa, Johji.

In: Cancer Science, Vol. 98, No. 7, 07.2007, p. 1070-1077.

Research output: Contribution to journalArticle

Kawasaki, T, Yokoi, S, Tsuda, H, Izumi, H, Kozaki, KI, Aida, S, Ozeki, Y, Yoshizawa, Y, Imoto, I & Inazawa, J 2007, 'BCL2L2 is a probable target for novel 14q11.2 amplification detected in a non-small cell lung cancer cell line', Cancer Science, vol. 98, no. 7, pp. 1070-1077. https://doi.org/10.1111/j.1349-7006.2007.00491.x
Kawasaki, Tsutomu ; Yokoi, Sana ; Tsuda, Hitoshi ; Izumi, Hiroyuki ; Kozaki, Ken Ichi ; Aida, Shinsuke ; Ozeki, Yuichi ; Yoshizawa, Yasuyuki ; Imoto, Issei ; Inazawa, Johji. / BCL2L2 is a probable target for novel 14q11.2 amplification detected in a non-small cell lung cancer cell line. In: Cancer Science. 2007 ; Vol. 98, No. 7. pp. 1070-1077.
@article{bde04effa7f44e43857593e25c5f8390,
title = "BCL2L2 is a probable target for novel 14q11.2 amplification detected in a non-small cell lung cancer cell line",
abstract = "Amplification of chromosomal DNA is thought to be one of the mechanisms that activates cancer-related genes in tumors. In a previous genome-wide screening of DNA copy number aberrations in a panel of non-small cell lung cancer (NSCLC) cell lines using an in-house bacterial artificial chromosome-based array, we identified a novel amplification at 14q11.2 in HUT29 cells derived from human lung adenocarcinoma. To identify the most likely target for the 14q11.2 amplification, we determined the extent of the amplicon by fluorescence in.situ hybridization and then analyzed NSCLC cell lines for the expression levels of 28 genes present within the 1-Mb amplified region. Significant overexpression in the HUT29 cell line with amplification, relatively frequent overexpression in additional NSCLC cell lines compared with an immortalized normal lung epithelial cell line, and reported information about the function of each candidate gene prompted us to characterize the BCL2-like2 (BCL2L2) gene, a prosurvival member of the BCL2 family, as the most likely target for the 14q11.2 amplicon. Immunohistochemical analysis of 61 primary cases of lung adenocarcinoma demonstrated that BCL2L2 overexpression was significantly associated with tumor stage and differentiation status, and tended to be associated with a poorer prognosis. Downregulation of BCL2L2 expression using small interfering RNA dramatically inhibited the growth of HUT29 cells, but showed no effect on anticancer reagent-induced cell death of the same cell line. These findings demonstrate that overexpressed BCL2L2, through amplification or other mechanisms, promotes the growth of NSCLC, especially the adenocarcinoma subtype, and might be a therapeutic target.",
author = "Tsutomu Kawasaki and Sana Yokoi and Hitoshi Tsuda and Hiroyuki Izumi and Kozaki, {Ken Ichi} and Shinsuke Aida and Yuichi Ozeki and Yasuyuki Yoshizawa and Issei Imoto and Johji Inazawa",
year = "2007",
month = "7",
doi = "10.1111/j.1349-7006.2007.00491.x",
language = "English",
volume = "98",
pages = "1070--1077",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "7",

}

TY - JOUR

T1 - BCL2L2 is a probable target for novel 14q11.2 amplification detected in a non-small cell lung cancer cell line

AU - Kawasaki, Tsutomu

AU - Yokoi, Sana

AU - Tsuda, Hitoshi

AU - Izumi, Hiroyuki

AU - Kozaki, Ken Ichi

AU - Aida, Shinsuke

AU - Ozeki, Yuichi

AU - Yoshizawa, Yasuyuki

AU - Imoto, Issei

AU - Inazawa, Johji

PY - 2007/7

Y1 - 2007/7

N2 - Amplification of chromosomal DNA is thought to be one of the mechanisms that activates cancer-related genes in tumors. In a previous genome-wide screening of DNA copy number aberrations in a panel of non-small cell lung cancer (NSCLC) cell lines using an in-house bacterial artificial chromosome-based array, we identified a novel amplification at 14q11.2 in HUT29 cells derived from human lung adenocarcinoma. To identify the most likely target for the 14q11.2 amplification, we determined the extent of the amplicon by fluorescence in.situ hybridization and then analyzed NSCLC cell lines for the expression levels of 28 genes present within the 1-Mb amplified region. Significant overexpression in the HUT29 cell line with amplification, relatively frequent overexpression in additional NSCLC cell lines compared with an immortalized normal lung epithelial cell line, and reported information about the function of each candidate gene prompted us to characterize the BCL2-like2 (BCL2L2) gene, a prosurvival member of the BCL2 family, as the most likely target for the 14q11.2 amplicon. Immunohistochemical analysis of 61 primary cases of lung adenocarcinoma demonstrated that BCL2L2 overexpression was significantly associated with tumor stage and differentiation status, and tended to be associated with a poorer prognosis. Downregulation of BCL2L2 expression using small interfering RNA dramatically inhibited the growth of HUT29 cells, but showed no effect on anticancer reagent-induced cell death of the same cell line. These findings demonstrate that overexpressed BCL2L2, through amplification or other mechanisms, promotes the growth of NSCLC, especially the adenocarcinoma subtype, and might be a therapeutic target.

AB - Amplification of chromosomal DNA is thought to be one of the mechanisms that activates cancer-related genes in tumors. In a previous genome-wide screening of DNA copy number aberrations in a panel of non-small cell lung cancer (NSCLC) cell lines using an in-house bacterial artificial chromosome-based array, we identified a novel amplification at 14q11.2 in HUT29 cells derived from human lung adenocarcinoma. To identify the most likely target for the 14q11.2 amplification, we determined the extent of the amplicon by fluorescence in.situ hybridization and then analyzed NSCLC cell lines for the expression levels of 28 genes present within the 1-Mb amplified region. Significant overexpression in the HUT29 cell line with amplification, relatively frequent overexpression in additional NSCLC cell lines compared with an immortalized normal lung epithelial cell line, and reported information about the function of each candidate gene prompted us to characterize the BCL2-like2 (BCL2L2) gene, a prosurvival member of the BCL2 family, as the most likely target for the 14q11.2 amplicon. Immunohistochemical analysis of 61 primary cases of lung adenocarcinoma demonstrated that BCL2L2 overexpression was significantly associated with tumor stage and differentiation status, and tended to be associated with a poorer prognosis. Downregulation of BCL2L2 expression using small interfering RNA dramatically inhibited the growth of HUT29 cells, but showed no effect on anticancer reagent-induced cell death of the same cell line. These findings demonstrate that overexpressed BCL2L2, through amplification or other mechanisms, promotes the growth of NSCLC, especially the adenocarcinoma subtype, and might be a therapeutic target.

UR - http://www.scopus.com/inward/record.url?scp=34249904163&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249904163&partnerID=8YFLogxK

U2 - 10.1111/j.1349-7006.2007.00491.x

DO - 10.1111/j.1349-7006.2007.00491.x

M3 - Article

VL - 98

SP - 1070

EP - 1077

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 7

ER -